Showing 1 - 9 results of 9 for search 'Leticia Kuri-Cervantes', query time: 0.03s
Refine Results
-
1
Phenotypic Characterization of SLex+ and CLA+ CD4+ T Cells by Leticia Kuri-Cervantes, Maria Betina Pampena, Michael R. Betts
Published 2020-12-01
Article -
2
-
3
Multivariate indicators of disease severity in COVID-19 by Joe Bean, Leticia Kuri-Cervantes, Michael Pennella, Michael R. Betts, Nuala J. Meyer, Wail M. Hassan
Published 2023-03-01
Article -
4
Sialyl-LewisX Glycoantigen Is Enriched on Cells with Persistent HIV Transcription during Therapy by Florent Colomb, Leila B. Giron, Leticia Kuri-Cervantes, Opeyemi S. Adeniji, Tongcui Ma, Harsh Dweep, Emilie Battivelli, Eric Verdin, Clovis S. Palmer, Hiroaki Tateno, Andrew V. Kossenkov, Nadia R. Roan, Michael R. Betts, Mohamed Abdel-Mohsen
Published 2020-08-01
Article -
5
Assessment of HIV-1 integration in tissues and subsets across infection stages by Vincent H. Wu, Christopher L. Nobles, Leticia Kuri-Cervantes, Kevin McCormick, John K. Everett, Son Nguyen, Perla M. del Rio Estrada, Mauricio González-Navarro, Fernanda Torres-Ruiz, Santiago Ávila-Ríos, Gustavo Reyes-Terán, Frederic D. Bushman, Michael R. Betts
Published 2020-12-01
Article -
6
Siglec-9 defines and restrains a natural killer subpopulation highly cytotoxic to HIV-infected cells. by Opeyemi S Adeniji, Leticia Kuri-Cervantes, Chenfei Yu, Ziyang Xu, Michelle Ho, Glen M Chew, Cecilia Shikuma, Costin Tomescu, Ashley F George, Nadia R Roan, Lishomwa C Ndhlovu, Qin Liu, Kar Muthumani, David B Weiner, Michael R Betts, Han Xiao, Mohamed Abdel-Mohsen
Published 2021-11-01
Article -
7
Siglec-9 defines and restrains a natural killer subpopulation highly cytotoxic to HIV-infected cells by Opeyemi S. Adeniji, Leticia Kuri-Cervantes, Chenfei Yu, Ziyang Xu, Michelle Ho, Glen M. Chew, Cecilia Shikuma, Costin Tomescu, Ashley F. George, Nadia R. Roan, Lishomwa C. Ndhlovu, Qin Liu, Kar Muthumani, David B. Weiner, Michael R. Betts, Han Xiao, Mohamed Abdel-Mohsen
Published 2021-11-01
Article -
8
Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection by Noah J Silverstein, Yetao Wang, Zachary Manickas-Hill, Claudia Carbone, Ann Dauphin, Brittany P Boribong, Maggie Loiselle, Jameson Davis, Maureen M Leonard, Leticia Kuri-Cervantes, MGH COVID-19 Collection & Processing Team, Nuala J Meyer, Michael R Betts, Jonathan Z Li, Bruce D Walker, Xu G Yu, Lael M Yonker, Jeremy Luban
Published 2022-03-01
Article -
9
Validating a Proteomic Signature of Severe COVID-19 by Christopher V. Cosgriff, MD, MPH, Todd A. Miano, PhD, PharmD, Divij Mathew, PhD, Alexander C. Huang, MD, PhD, Heather M. Giannini, MD, MS, Leticia Kuri-Cervantes, PhD, M. Betina Pampena, PhD, Caroline A. G. Ittner, PhD, Ariel R. Weisman, MS, Roseline S. Agyekum, BS, Thomas G. Dunn, BS, Oluwatosin Oniyide, BS, Alexandra P. Turner, BS, Kurt D’Andrea, BS, Sharon Adamski, BS, Allison R. Greenplate, PhD, Brian J. Anderson, MD, MSCE, Michael O. Harhay, PhD, Tiffanie K. Jones, MD, MPH, MSCE, John P. Reilly, MD, MSCE, Nilam S. Mangalmurti, MD, Michael G. S. Shashaty, MD, MSCE, Michael R. Betts, PhD, E. John Wherry, PhD, Nuala J. Meyer, MD, MS
Published 2022-12-01
Article